- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
61 result(s) found for: Cerebellar.
Displaying page 1 of 4.
EudraCT Number: 2017-000810-44 | Sponsor Protocol Number: FSJD-PMM2-2016 | Start Date*: 2017-05-31 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: Phase II clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with PMM2-CDG deficiency. | |||||||||||||
Medical condition: Cerebellar syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005312-26 | Sponsor Protocol Number: FACEG | Start Date*: 2013-03-18 | |||||||||||
Sponsor Name:Hospital of the University of Munich, Grosshadern | |||||||||||||
Full Title: Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder | |||||||||||||
Medical condition: cerebellar gait disorder, cerebellar ataxia, sensorimotor adaption and ocular motor disorders, postural sway, dysarthria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006156-37 | Sponsor Protocol Number: FA_BBK_8 | Start Date*: 2012-07-10 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. | |||||||||||||
Medical condition: FRIEDREICH ATAXIA | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019737-94 | Sponsor Protocol Number: ARPA-IGF1-2010 | Start Date*: 2010-07-13 | |||||||||||
Sponsor Name:FIBHULP | |||||||||||||
Full Title: ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA | |||||||||||||
Medical condition: Ataxia cerebelosa degenerativa de grado leve a moderado | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003084-34 | Sponsor Protocol Number: GCSF_FRDA_v1 | Start Date*: 2018-01-22 | ||||||||||||||||
Sponsor Name:University of Bristol | ||||||||||||||||||
Full Title: The pharmacological effects of granulocyte-colony stimulating factor (GCSF) on frataxin expression in patients with Friedreich Ataxia | ||||||||||||||||||
Medical condition: Friedreich Ataxia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005414-40 | Sponsor Protocol Number: LEV-SM-2006 | Start Date*: 2007-12-21 | |||||||||||
Sponsor Name:AZIENDA SANITARIA N. 3 GENOVESE | |||||||||||||
Full Title: Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study | |||||||||||||
Medical condition: Patients with an established and stable Multiple Sclerosis (according to Poser criteria). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000197-53 | Sponsor Protocol Number: 2011-000197-53 | Start Date*: 2011-04-15 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: Effects of Potassium Sparing Diuretics on Potassium Urinary Output, Plasma Levels and Cardiac Arrhythmias in Neurocritical Care Patients Receiving Mannitol Therapy for Cerebral Edema: double blind,... | |||||||||||||
Medical condition: Acute Cerebral Edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016317-20 | Sponsor Protocol Number: SCA_LITIO_12 | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: PILOT STUDY TO ASSESS SAFETY AND TOLERABILITY OF LITHIUM ON SPINOCEREBELLAR ATAXIA OF TYPE 2 | |||||||||||||
Medical condition: Spinocerebellar ataxia type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000460-34 | Sponsor Protocol Number: ALCAT | Start Date*: 2015-11-18 |
Sponsor Name:Hospital of the University of Munich | ||
Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) | ||
Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005167-33 | Sponsor Protocol Number: 1210 | Start Date*: 2010-03-29 |
Sponsor Name:Charité University Medicine Berlin | ||
Full Title: Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease | ||
Medical condition: Patients with cerebellar ataxia with coordination deficits in walking, upper and lower limb movements and oculomtoor coordination deficits are included in the trial. The cause of their atayia is e... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004650-34 | Sponsor Protocol Number: GR-2011-02348985 | Start Date*: 2016-06-27 | |||||||||||
Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO | |||||||||||||
Full Title: Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia | |||||||||||||
Medical condition: Multiple sclerosis with cerebellar ataxia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018157-23 | Sponsor Protocol Number: D0490C00014 | Start Date*: 2010-11-30 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ... | |||||||||||||
Medical condition: Multiple system atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001577-33 | Sponsor Protocol Number: D24-DIPG | Start Date*: 2016-11-03 |
Sponsor Name:Clínica Universidad de Navarra | ||
Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001481-23 | Sponsor Protocol Number: P160927J | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 | |||||||||||||
Medical condition: SCA2 patients, both gender, at least 18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019348-37 | Sponsor Protocol Number: CLDE225X2104 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway | ||||||||||||||||||||||||||||||||||||||
Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002571-16 | Sponsor Protocol Number: MBP8298-01 Amendment 04 | Start Date*: 2007-06-29 | |||||||||||
Sponsor Name:BioMS Technology Corp | |||||||||||||
Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022189-28 | Sponsor Protocol Number: BO25041 | Start Date*: 2011-08-12 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR ... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Newly diagnosed high-grade glioma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SE (Completed) HU (Completed) FR (Completed) ES (Completed) DK (Completed) FI (Prematurely Ended) NL (Completed) IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016377-15 | Sponsor Protocol Number: MSA_LITIO_13 | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY | |||||||||||||
Medical condition: Muliple system atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003903-35 | Sponsor Protocol Number: : NUTH-2005-03384 | Start Date*: 2006-01-19 |
Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust | ||
Full Title: : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis | ||
Medical condition: Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004802-70 | Sponsor Protocol Number: APHP200491 | Start Date*: 2021-08-03 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris | ||
Full Title: Impact of post-ARDS COVID sedation on late neuroinflammation | ||
Medical condition: All patients who have developed and survived ARDS linked to COVID-19 infection, admitted to intensive care units, meeting the study's inclusion criteria may be included in this research. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
